Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers

Hyuna Sung; Montserrat Garcia-Closas; Jenny Chang-Claude; Fiona M. Blows; H. Raza Ali; Jonine Figueroa; Heli Nevanlinna; Rainer Fagerholm; Paivi Heikkilä; Carl Blomqvist; Graham G. Giles; Roger L. Milne; Melissa C. Southey; Catriona McLean; Arto Mannermaa; Veli Matti Kosma; Vesa Kataja; Reijo Sironen; Fergus J. Couch; Janet E. Olson; Emily Hallberg; Curtis Olswold; Angela Cox; Simon S. Cross; Peter Kraft; Rulla M. Tamimi; A. Heather Eliassen; Marjanka K. Schmidt; Manjeet K. Bolla; Qin Wang; Douglas Easton; William J. Howat; Penny Coulson; Paul D.P. Pharoah; Mark E. Sherman; Xiaohong R. Yang

doi:10.1038/bjc.2015.437

Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers

Hyuna Sung, Montserrat Garcia-Closas, Jenny Chang-Claude, Fiona M. Blows, H. Raza Ali, Jonine Figueroa, Heli Nevanlinna, Rainer Fagerholm, Paivi Heikkilä, Carl Blomqvist, Graham G. Giles, Roger L. Milne, Melissa C. Southey, Catriona McLean, Arto Mannermaa, Veli Matti Kosma, Vesa Kataja, Reijo Sironen, Fergus J. Couch, Janet E. OlsonEmily Hallberg, Curtis Olswold, Angela Cox, Simon S. Cross, Peter Kraft, Rulla M. Tamimi, A. Heather Eliassen, Marjanka K. Schmidt, Manjeet K. Bolla, Qin Wang, Douglas Easton, William J. Howat, Penny Coulson, Paul D.P. Pharoah, Mark E. Sherman, Xiaohong R. Yang

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Background:Luminal A breast cancer defined as hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative is known to be heterogeneous. Previous study showed that luminal A tumours with the expression of basal markers ((cytokeratin (CK) 5 or CK5/6) or epidermal growth factor receptor (EGFR)) were associated with poorer prognosis compared with those that stained negative for basal markers. Prompted by this study, we assessed whether tumour characteristics and risk factors differed by basal marker status within luminal A tumours.Methods:We pooled 5040 luminal A cases defined by immunohistochemistry (4490 basal-negative ((CK5 (or CK5/6))- and EGFR-) and 550 basal-positive ((CK5 (or CK5/6+)) or EGFR+)) from eight studies participating in the Breast Cancer Association Consortium. Case-case comparison was performed using unconditional logistic regression.Results:Tumour characteristics and risk factors did not vary significantly by the expression of basal markers, although results suggested that basal-positive luminal tumours tended to be smaller and node negative, and were more common in women with a positive family history and lower body mass index.Conclusions:Most established breast cancer risk factors were similar in basal-positive and basal-negative luminal A tumours. The non-significant but suggestive differences in tumour features and family history warrant further investigations.

Original language	English (US)
Pages (from-to)	298-304
Number of pages	7
Journal	British journal of cancer
Volume	114
Issue number	3
DOIs	https://doi.org/10.1038/bjc.2015.437
State	Published - Feb 2 2016

Keywords

CK5/6
EGFR
breast cancer
luminal A tumour
risk factors
tumour characteristics

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/bjc.2015.437

Cite this

Sung, H., Garcia-Closas, M., Chang-Claude, J., Blows, F. M., Ali, H. R., Figueroa, J., Nevanlinna, H., Fagerholm, R., Heikkilä, P., Blomqvist, C., Giles, G. G., Milne, R. L., Southey, M. C., McLean, C., Mannermaa, A., Kosma, V. M., Kataja, V., Sironen, R., Couch, F. J., ... Yang, X. R. (2016). Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers. British journal of cancer, 114(3), 298-304. https://doi.org/10.1038/bjc.2015.437

Sung, H, Garcia-Closas, M, Chang-Claude, J, Blows, FM, Ali, HR, Figueroa, J, Nevanlinna, H, Fagerholm, R, Heikkilä, P, Blomqvist, C, Giles, GG, Milne, RL, Southey, MC, McLean, C, Mannermaa, A, Kosma, VM, Kataja, V, Sironen, R, Couch, FJ , Olson, JE, Hallberg, E, Olswold, C, Cox, A, Cross, SS, Kraft, P, Tamimi, RM, Eliassen, AH, Schmidt, MK, Bolla, MK, Wang, Q, Easton, D, Howat, WJ, Coulson, P, Pharoah, PDP, Sherman, ME & Yang, XR 2016, 'Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers', British journal of cancer, vol. 114, no. 3, pp. 298-304. https://doi.org/10.1038/bjc.2015.437

@article{8902087f08fd490b87edcfcc6fcf3504,

title = "Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers",

abstract = "Background:Luminal A breast cancer defined as hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative is known to be heterogeneous. Previous study showed that luminal A tumours with the expression of basal markers ((cytokeratin (CK) 5 or CK5/6) or epidermal growth factor receptor (EGFR)) were associated with poorer prognosis compared with those that stained negative for basal markers. Prompted by this study, we assessed whether tumour characteristics and risk factors differed by basal marker status within luminal A tumours.Methods:We pooled 5040 luminal A cases defined by immunohistochemistry (4490 basal-negative ((CK5 (or CK5/6))- and EGFR-) and 550 basal-positive ((CK5 (or CK5/6+)) or EGFR+)) from eight studies participating in the Breast Cancer Association Consortium. Case-case comparison was performed using unconditional logistic regression.Results:Tumour characteristics and risk factors did not vary significantly by the expression of basal markers, although results suggested that basal-positive luminal tumours tended to be smaller and node negative, and were more common in women with a positive family history and lower body mass index.Conclusions:Most established breast cancer risk factors were similar in basal-positive and basal-negative luminal A tumours. The non-significant but suggestive differences in tumour features and family history warrant further investigations.",

keywords = "CK5/6, EGFR, breast cancer, luminal A tumour, risk factors, tumour characteristics",

author = "Hyuna Sung and Montserrat Garcia-Closas and Jenny Chang-Claude and Blows, {Fiona M.} and Ali, {H. Raza} and Jonine Figueroa and Heli Nevanlinna and Rainer Fagerholm and Paivi Heikkil{\"a} and Carl Blomqvist and Giles, {Graham G.} and Milne, {Roger L.} and Southey, {Melissa C.} and Catriona McLean and Arto Mannermaa and Kosma, {Veli Matti} and Vesa Kataja and Reijo Sironen and Couch, {Fergus J.} and Olson, {Janet E.} and Emily Hallberg and Curtis Olswold and Angela Cox and Cross, {Simon S.} and Peter Kraft and Tamimi, {Rulla M.} and Eliassen, {A. Heather} and Schmidt, {Marjanka K.} and Bolla, {Manjeet K.} and Qin Wang and Douglas Easton and Howat, {William J.} and Penny Coulson and Pharoah, {Paul D.P.} and Sherman, {Mark E.} and Yang, {Xiaohong R.}",

note = "Publisher Copyright: {\textcopyright} 2016 Cancer Research UK.",

year = "2016",

month = feb,

day = "2",

doi = "10.1038/bjc.2015.437",

language = "English (US)",

volume = "114",

pages = "298--304",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers

AU - Sung, Hyuna

AU - Garcia-Closas, Montserrat

AU - Chang-Claude, Jenny

AU - Blows, Fiona M.

AU - Ali, H. Raza

AU - Figueroa, Jonine

AU - Nevanlinna, Heli

AU - Fagerholm, Rainer

AU - Heikkilä, Paivi

AU - Blomqvist, Carl

AU - Giles, Graham G.

AU - Milne, Roger L.

AU - Southey, Melissa C.

AU - McLean, Catriona

AU - Mannermaa, Arto

AU - Kosma, Veli Matti

AU - Kataja, Vesa

AU - Sironen, Reijo

AU - Couch, Fergus J.

AU - Olson, Janet E.

AU - Hallberg, Emily

AU - Olswold, Curtis

AU - Cox, Angela

AU - Cross, Simon S.

AU - Kraft, Peter

AU - Tamimi, Rulla M.

AU - Eliassen, A. Heather

AU - Schmidt, Marjanka K.

AU - Bolla, Manjeet K.

AU - Wang, Qin

AU - Easton, Douglas

AU - Howat, William J.

AU - Coulson, Penny

AU - Pharoah, Paul D.P.

AU - Sherman, Mark E.

AU - Yang, Xiaohong R.

PY - 2016/2/2

Y1 - 2016/2/2

N2 - Background:Luminal A breast cancer defined as hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative is known to be heterogeneous. Previous study showed that luminal A tumours with the expression of basal markers ((cytokeratin (CK) 5 or CK5/6) or epidermal growth factor receptor (EGFR)) were associated with poorer prognosis compared with those that stained negative for basal markers. Prompted by this study, we assessed whether tumour characteristics and risk factors differed by basal marker status within luminal A tumours.Methods:We pooled 5040 luminal A cases defined by immunohistochemistry (4490 basal-negative ((CK5 (or CK5/6))- and EGFR-) and 550 basal-positive ((CK5 (or CK5/6+)) or EGFR+)) from eight studies participating in the Breast Cancer Association Consortium. Case-case comparison was performed using unconditional logistic regression.Results:Tumour characteristics and risk factors did not vary significantly by the expression of basal markers, although results suggested that basal-positive luminal tumours tended to be smaller and node negative, and were more common in women with a positive family history and lower body mass index.Conclusions:Most established breast cancer risk factors were similar in basal-positive and basal-negative luminal A tumours. The non-significant but suggestive differences in tumour features and family history warrant further investigations.

AB - Background:Luminal A breast cancer defined as hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative is known to be heterogeneous. Previous study showed that luminal A tumours with the expression of basal markers ((cytokeratin (CK) 5 or CK5/6) or epidermal growth factor receptor (EGFR)) were associated with poorer prognosis compared with those that stained negative for basal markers. Prompted by this study, we assessed whether tumour characteristics and risk factors differed by basal marker status within luminal A tumours.Methods:We pooled 5040 luminal A cases defined by immunohistochemistry (4490 basal-negative ((CK5 (or CK5/6))- and EGFR-) and 550 basal-positive ((CK5 (or CK5/6+)) or EGFR+)) from eight studies participating in the Breast Cancer Association Consortium. Case-case comparison was performed using unconditional logistic regression.Results:Tumour characteristics and risk factors did not vary significantly by the expression of basal markers, although results suggested that basal-positive luminal tumours tended to be smaller and node negative, and were more common in women with a positive family history and lower body mass index.Conclusions:Most established breast cancer risk factors were similar in basal-positive and basal-negative luminal A tumours. The non-significant but suggestive differences in tumour features and family history warrant further investigations.

KW - CK5/6

KW - EGFR

KW - breast cancer

KW - luminal A tumour

KW - risk factors

KW - tumour characteristics

UR - http://www.scopus.com/inward/record.url?scp=84956710941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956710941&partnerID=8YFLogxK

U2 - 10.1038/bjc.2015.437

DO - 10.1038/bjc.2015.437

M3 - Article

C2 - 26679376

AN - SCOPUS:84956710941

SN - 0007-0920

VL - 114

SP - 298

EP - 304

JO - British journal of cancer

JF - British journal of cancer

IS - 3

ER -

Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this